Google
VXRT Stock Price & Analysis — Vaxart Inc (Healthcare >> Biotechnology)
VXRT FAQ
What is VXRT's P/E ratio?
Vaxart Inc (VXRT) currently trades at a P/E ratio of 2.09.
What is VXRT's ROE?
Vaxart Inc reports a Return on Equity (ROE) of 39.42%.
What is VXRT's dividend yield?
Vaxart Inc offers a dividend yield of 0.00%.
What is VXRT's Quality Score?
Our AI rates VXRT's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy VXRT?
Our AI Timing Score for VXRT is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does VXRT belong to?
Vaxart Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
VXRT AI Analysis Summary
Our AI summary for VXRT: Vaxart Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 2.09, ROE of 39.42%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.55
Price
0.03
(5.58%)
Day Change
|
|
|---|
VXRT, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
58% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
184
|
| Magic Formula Rank by ROE |
184
|
| Magic Formula Rank by ROIC |
104
|
| Price | 0.55 |
| PBV / Sector |
1.34 / 5.20
GOOD
|
| Earning Per Share | 0.16 |
| PE / Sector |
2.09 / 19.97
GREAT
|
| PEG or PE/Growth / Sector |
-0.03 / 1.22
|
| Average 1M Daily Value |
0.07 M
GREAT
|
| Average 1W Daily Value |
0.06 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:41 |
| Symbol | VXRT |
| Name | VAXART INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 242.04 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 125.86 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 310 Utah Avenue, South San Francisco, CA, United States, 94080
Phone: 650 550 3500
Website: https://vaxart.com
Employees: 65
Sector: Healthcare >> Biotechnology
Description: Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap